Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70350 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Sijie Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, China Innovation Center of Roche, Shanghai, China. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents, Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer therapeutics. Monomethyl auristatin E is the most frequently used payload (in five approved ADCs), followed by deruxtecan and calicheamicin. It is noted that ADCs using the same linker and payload often share similar PK and catabolism/metabolism characteristics, and thus providing opportunities for their streamlined development provided the applicant owns or has a right of reference of underlying data when it is necessary. In this review, we summarize the key clinical pharmacology considerations by payload class, using approved ADCs as case examples to support development and regulatory approval. We then compare the data and discuss how to leverage prior experience of ADCs, either qualitatively or quantitatively. These data and strategy insights will help researchers to integrate data from platform ADCs that share the same linker‐payload and apply broader ADC‐related insights, thereby accelerating future ADC developments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Roche Pharma Research and Early Development, China Innovation Center of Roche, Shanghai, China.
- Department of Pharmaceutical Sciences, University of the Pacific, Stockton, California, USA.
- Third Arc Bio Inc., Lower Gwynedd, Pennsylvania, USA.
- Genentech, South San Francisco, California, USA.
Zitieren
APA
Lu, S., Xiao, Q., Qian, L., Sun, S., Zhou, Z., Liao, M. Z., & Li, C. (2026). Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70350
Vancouver
Lu S, Xiao Q, Qian L, Sun S, Zhou Z, Liao MZ, et al. Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70350
BibTeX
@article{Lu2026,
author = {Lu, Sijie and Xiao, Qingqing and Qian, Lixuan and Sun, Siyuan and Zhou, Zhu and Liao, Michael Z and Li, Chunze},
title = {Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70350}
}
EUVIMED